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ommunication between different signaling pathways
enables cells to coordinate the responses to diverse
 
environmental signals. Activation of the trans-
membrane growth factor precursors plays a critical role in
this communication and often involves metalloprotease-
mediated proteolysis. Stimulation of G protein–coupled
receptors (GPCR) transactivates the EGF receptors (EGFRs),
which occurs via a metalloprotease-dependent cleavage of
heparin-binding EGF (HB-EGF). However, the metallo-
protease mediating the transactivation remains elusive. We
show that the integral membrane metalloprotease Kuzbanian
(KUZ; ADAM10), which controls Notch signaling in
C
 
Drosophila
 
, stimulates GPCR transactivation of EGFR. Upon
stimulation of the bombesin receptors, KUZ increases the
docking and activation of adaptors Src homology 2 domain–
containing protein and Gab1 on the EGFR, and activation of
Ras and Erk. In contrast, transfection of a protease domain–
deleted KUZ, or blocking endogenous KUZ by morpholino
antisense oligonucleotides, suppresses the transactivation. The
effect of KUZ on shedding of HB-EGF and consequent trans-
activation of the EGFR depends on its metalloprotease activity.
GPCR activation enhances the association of KUZ and its
substrate HB-EGF with tetraspanin CD9. Thus, KUZ regulates
the relay between the GPCR and EGFR signaling pathways.
 
Introduction
 
Cells sense diverse extracellular signals with different types
of receptors on the cell surface, and transduce these signals
into the cells through distinct signal pathways. But there is
also significant crosstalk between the signaling pathways.
In many cases, crosstalk occurs at the level of sharing
components in the pathway, such as MAP kinases and
other intracellular kinases. Crosstalk also occurs directly
between membrane receptors; for example, stimulation of
G protein–coupled receptors (GPCRs)* leads to the activation
of EGF receptors (EGFRs) (Daub et al., 1996; Carpenter,
1999; Pierce et al., 2001a). This transactivation of EGFR
by GPCR occurs via a release of heparin-binding EGF
(HB-EGF), which is blocked by metalloprotease inhibitor
(Prenzel et al., 1999).
Metalloproteases regulate cell behavior by modifying both
the macro- and microenvironment of cells during their normal
growth and development (Werb, 1997; Werb and Yan,
1998). Misregulation of metalloprotease activities contributes
to many pathological processes, including tumorigenesis
(Sternlicht et al., 1999). The integral membrane metallo-
proteases with a disintegrin domain (ADAMs) cleave various
membrane-bound proteins, including ligands, receptors,
and ligand–receptor complexes (Black and White, 1998;
Blobel, 2000). Among the well-studied ADAMs are tu-
mor necrosis factor (TNF)-
 
 
 
–converting enzyme (TACE;
ADAM17), which not only cleaves TNF-
 
 
 
 but also converts
pro-TGF
 
 
 
 precursors to active TGF
 
 
 
 (Peschon et al.,
1998), and Kuzbanian (KUZ; ADAM10), which is a key
regulator of Notch signaling pathways in 
 
Drosophila
 
 possibly
because of its metalloprotease activity (Pan and Rubin,
1997; Qi et al., 1999). Thus, proteolysis by ADAMs can
change the active state of surface molecular complexes,
affecting the signaling pathways inside cells.
Metalloprotease-mediated release of EGFR ligands not only
contributes to a normal development process, as revealed with
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the metalloprotease-deficient mice, but also plays important
roles in the abnormal growth of tumor cells. Inhibition
of metalloprotease-mediated EGFR ligand shedding re-
duces the proliferation and migration of breast cancer
cells (Dong et al., 1999). Moreover, so-called autocrine
growth of tumor cells is often EGFR dependent, and
GPCR ligands, such as bombesin, also act as growth fac-
tors. In PC3 prostate cancer cells, the metalloprotease
inhibitor BB94 inhibits bombesin- and phorbol ester–
induced EGFR transactivation (Prenzel et al., 1999). Thus,
metalloproteases are an integral part of this EGFR-depen-
dent autocrine growth pathway. However, understanding
the pathway from GPCR to EGFR activation has been
limited by the lack of knowledge about the metallopro-
tease involved. Several metalloproteases are capable of
cleaving EGFR ligands, but there is no evidence that they
support the EGFR transactivation by GPCR. For exam-
ple, ADAM9 cleaves HB-EGF when PKC
 
 
 
 is activated,
but neither wild-type nor dominant-negative ADAM9 af-
fects the EGFR transactivation (Izumi et al., 1998). Here
we report that the metalloprotease KUZ (ADAM10), de-
scribed initially as the regulator of Notch signaling, sup-
ports the GPCR-induced transactivation of the EGFR
signaling pathway.
 
Results and discussion
 
To identify the metalloprotease that mediates the transacti-
vation of EGFR, we transfected COS7 cells with mouse
KUZ and other metalloprotease disintegrins (ADAMs), and
examined EGFR activation after activating the transfected
cells with GPCR ligands. Stimulation of COS7 cells with
the GPCR ligands lysophosphatidic acid (LPA) and bombe-
sin significantly increased EGFR activation, confirming
that, indeed, there were strong interactions between the
GPCR and EGFR signaling pathways (Fig. 1, A and B).
Transfection of KUZ further augmented GPCR-induced
EGFR phosphorylation. The enhancement of EGFR phos-
phorylation in the presence of transfected KUZ was moder-
ate but significant, ranging from a 1.5- to 3.2-fold increase
over the transactivation mediated by the endogenous pro-
tease (Fig. 1 C). These results suggest that KUZ enhances
EGFR transactivation by GPCR.
In contrast to the transfection of wild-type KUZ, transfec-
tion of COS7 cells with a KUZ mutant that lacks the metal-
loprotease domain (K
 
 
 
MP) and acts as a dominant-negative
mutation in 
 
Drosophila 
 
reduced the GPCR-induced EGFR
phosphorylation. In fact, after bombesin treatment, the level
of EGFR phosphorylation in the K
 
 
 
MP-transfected cells
was lower than in cells transfected with a vector plasmid, in-
Figure 1. KUZ mediates GPCR transactivation of EGFR in 
COS7 cells. (A and B) KUZ, but not K MP, stimulates the LPA- 
and bombesin-induced EGFR phosphorylation. EGFR activation 
was detected in precipitated EGFR with antiphosphotyrosine 
antibody 4G10 and the amount of EGFR was detected with goat 
anti-EGFR antibody in the same blot. (C) Increase of EGFR 
phosphorylation induced by bombesin in the presence of 
exogenous KUZ or K MP. Phosphorylation was quantified with NIH Image 1.62 (n   6 sets of experiments). (D) Bombesin-induced EGFR 
phosphorylation depends on HB-EGF and EGFR kinase. COS7 cells were pretreated for 20 min with CRM197 (lanes 3 and 4) or specific EGFR 
kinase inhibitor AG1487 (lanes 5 and 6) before treatment with bombesin. (E–G) KUZ is more effective than ADAM17 (TACE) or ADAM15 in 
mediating bombesin-induced EGFR transactivation. Transactivation of EGFR (E–G) and activation of the downstream adaptor SHC (E) are 
shown in cells transfected with equal amounts of plasmids containing (E) wild-type TACE and KUZ or (F) COOH-terminal Flag-tagged TACE, 
ADAM15, and KUZ. The amount of ADAMs expressed is shown in an immunoblot of cell lysates with anti-Flag antibody M2. Results 
(n   3 sets of experiments) are quantified in G. 
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dicating that K
 
 
 
MP blocks the endogenous metallopro-
tease-mediated EGFR transactivation in COS7 cells. In cells
transfected with KUZ, the phosphorylation of EGFR in the
presence of GPCR ligand was effectively inhibited by
CRM197, an inactivated diphtheria toxin that specifically
binds to HB-EGF, and by the EGFR kinase inhibitor
AG1478, confirming that the effect of KUZ on increased
EGFR phosphorylation is due to the activation of the EGFR
ligand HB-EGF by GPCR signaling (Fig. 1 D). Thus, KUZ
appears to function as an intermediate between activated
GPCR and EGFR phosphorylation.
To test whether other ADAMs have the same effect on
EGFR transactivation in COS7 cells, we transfected the
same amount of plasmids carrying wild-type ADAM15,
TACE (ADAM17), and KUZ and similar constructs with a
Flag-tagged COOH terminus (Fig. 1, E–G). Bombesin in-
duced a fourfold increase of EGFR phosphorylation in vec-
tor-transfected cells and an eightfold increase in cells trans-
fected with wild-type KUZ, and increased phosphorylation
of all three isoforms of the adaptor Src homology 2 domain–
containing protein (SHC) (Fig. 1, E and G). However,
transfection of neither TACE nor ADAM15 increased
EGFR phosphorylation; in fact, they gave a reproducible de-
crease in phosphorylation (Fig. 1 G). The effect on EGFR
transactivation did not correlate with the expression level of
these ADAMs in COS7 cells. In fact, KUZ was expressed at
lower levels than either ADAM17 or ADAM15 (Fig. 1 F).
In COS7 cells, transfection of the evolutionarily related
ADAM9 or a dominant-negative ADAM9 had no effect on
EGFR transactivation (Izumi et al., 1998; Prenzel et al.,
1999). Therefore, KUZ appeared to be uniquely effective as
a mediator of EGFR transactivation in COS7 cells.
To assess the effects of KUZ on signaling pathways down-
stream of the transactivation of EGFR, we investigated the
docking and phosphorylation of proteins known to associate
with phosphorylated EGFR. Transfection of wild-type KUZ
increased, and of K
 
 
 
MP decreased, the bombesin-depen-
dent phosphorylation of SHC (Fig. 2 A) and of another
adaptor Gab1 (Fig. 2 B). KUZ, but not K
 
 
 
MP, increased
the amount of phosphorylated EGFR that coprecipitated
with SHC upon bombesin treatment (unpublished data),
indicating that KUZ facilitates the direct recruitment of
SHC by activated EGFR. Thus, KUZ increases the activa-
tion of signaling components docked on activated EGFR
upon stimulation of GPCR.
GPCRs, such as bombesin receptor, activate growth sig-
naling through both Ras-dependent and independent path-
ways. To test whether KUZ-mediated transactivation of
EGFR is an integral part of the mechanism by which
GPCRs activate the Ras pathway, we next examined the ef-
fect of KUZ on the activation of Ras, which links the acti-
vated EGFR to MAP kinase activation. Precipitation of acti-
vated Ras from the COS7 cell lysates with a fusion protein
containing the Ras-binding domain of Raf1 showed that
bombesin treatment significantly increased Ras activation
(Fig. 2 C). The expression of KUZ, but not K
 
 
 
MP, further
elevated the increase of activated Ras. The results demon-
strate that the metalloprotease KUZ contributes to the
GPCR activation of EGFR, which leads to the activation of
the Ras-dependent signaling pathway.
Antagonists of bombesin inhibit tumor growth in nude
mice seeded with PC3 cells, and their effects are EGFR de-
pendent, suggesting that EGFR is involved in bombesin-
induced tumor growth (Plonowski et al., 2000; Heasley,
2001). Interestingly, in preliminary studies, we have found
that the expression of KUZ increases with neoplastic pro-
Figure 2. KUZ stimulates, and blocking endogenous KUZ inhibits, 
the transactivation of signaling pathways downstream of EGFR. 
(A) Activation of all three forms of SHC and (B) Gab1 phosphorylation 
by GPCR are stimulated by transfecting KUZ, but not protease-
deleted K MP, into COS7 cells. (C) KUZ elevates GPCR-induced 
Ras activation in COS7 cells. The upper band, nonspecifically reactive 
to the anti-Ras antibody, is shown as the loading control. (D) Bombesin 
induces Erk1/2 activation in PC3 cells, which is partly due to the 
transactivation of EGFR and depends on HB-EGF release. PC3 cells 
were treated with CRM197 or AG1487 and then stimulated with 
bombesin. (E) Transfecting K MP suppresses Erk1/2 activation in 
PC3 cells. Active Erk1/2 was detected in bombesin-treated or untreated 
PC3 cells transfected with vector or K MP with anti–phospho-Erk1/2 
antibody. (F) Bombesin-induced Erk1/2 activation can be inhibited by 
an antisense morpholino oligonucleotide against ADAM10. Erk1/2 
phosphorylation was detected in lysates of PC3 treated with the 
morpholino anti-ADAM10 oligo (Anti-KUZ) and control oligo with 
the same base composition but in reverse order (Reverse-KUZ). The 
endogenous ADAM10 in antisense oligo–treated cells was 
detected with a polyclonal antibody to ADAM10 (KUZ). 
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gression in transgenic models of mouse prostate cancer
(unpublished data). Moreover, ADAM10, the human
homologue of KUZ, significantly increases with androgen
treatment in PC3 cells, whereas TACE expression is inhib-
ited (McCulloch et al., 2000). To assess whether endoge-
nous KUZ was involved in GPCR transactivation of the
EGFR signaling pathway in PC3 prostate cancer cells, we in-
vestigated the effect of KUZ on the activation of MAP ki-
nase (Erk1/2). Inhibition of EGFR kinase with AG1478 and
neutralization of HB-EGF with CRM197 both reduced
Erk1/2 phosphorylation by bombesin, suggesting that trans-
activation of EGFR is required, at least in part, for bombesin
to activate Erk signaling in PC3 cells (Fig. 2 D).
To determine whether PC3 cells require KUZ for this trans-
activation, we used two methods to inhibit endogenous KUZ
and then tested the response of the cells to bombesin. First,
transfecting K
 
 
 
MP suppressed transactivation of Erk1/2 by
bombesin (Fig. 2 E). Second, introduction of the specific anti-
sense morpholino oligonucleotide against ADAM10 inhibited
the bombesin-mediated transactivation of Erk1/2, whereas a
control oligonucleotide with same nucleotide sequence but in a
reverse orientation did not (Fig. 2 F), nor did the antisense oli-
gonucleotides against ADAMs 9 and 15 and TACE (unpub-
lished data). These results show that blocking KUZ inhibits
transactivation, implicating endogenous KUZ as a critical
player in GPCR transactivation of EGFR signaling.
The effect of KUZ on EGFR transactivation required its
metalloprotease activity. KUZ was involved in shedding
HB-EGF from COS7 cells. Stimulation of cells with bom-
besin increased the amount of shed HB-EGF in the medium.
KUZ enhanced the ability of bombesin to release HB-EGF
into the medium (Fig. 3 A). In contrast, K
 
 
 
MP blocked the
release of HB-EGF. These data show that KUZ is required
to shed HB-EGF. Inhibition of metalloprotease, using the
broad-spectrum inhibitor TAPI, also inhibited bombesin-
induced EGFR and SHC phosphorylation (Fig. 3 B). A single
E385A mutation causes the loss of KUZ metalloprotease ac-
tivity. When the mutant K(E-A) was introduced into COS7
cells, EGFR and SHC activation did not increase upon
bombesin treatment (Fig. 3 C). Therefore, metalloprotease
activity of KUZ is responsible for EGFR transactivation.
However, the ability to cleave HB-EGF alone is not suffi-
cient to cause the transactivation; an additional signaling step
is needed. Indeed, ADAM9 cleaves HB-EGF under the reg-
ulation of PKC, yet neither the wild-type nor the domi-
nant-negative ADAM9 affects the GPCR-induced EGFR
phosphorylation (Izumi et al., 1998; Prenzel et al., 1999).
Stimulation of GPCR unleashes an array of signaling media-
tors that may activate KUZ to support the EGFR transactiva-
tion. Interestingly, only Gi- and Gq-coupled GPCRs are as-
sociated with the transactivation of EGFR, and these GPCRs
activate p44/42 Erk. Whether Erk directly regulates the
cleavage of pro-TGF
 
 
 
 (Fan and Derynck, 1999) and c-Met
(Nath et al., 2001) in response to extracellular signals is unre-
solved, because dominant-negative MEK1 does not block the
transactivation resulting from HB-EGF shedding (Pierce et
al., 2001b). However, inhibition of Src kinase has a profound
effect on transactivation (Pierce et al., 2001b). It is conceiv-
able that kinases, such as Src activated by GPCR, can phos-
phorylate the cytoplasmic domain of ADAMs. The mecha-
nism by which this phosphorylation activates metalloprotease
remains elusive because the cytoplasmic domain of TACE is
dispensable in PMA-induced shedding (Reddy et al., 2000).
For shedding to occur in cis, KUZ would have to bind to
its substrate pro–HB-EGF. We therefore hypothesized that
GPCR affects KUZ activity by regulating the formation of
such a complex. Indeed, we found that the antibody to CD9,
a tetraspan transmembrane protein, precipitated not only
HB-EGF, but also KUZ from cell lysates, suggesting that they
coexist in the same molecular complex on the cell membrane
(Fig. 4). CD9 coprecipitated with two forms of HB-EGF, a
long 24-kD form and a short 18-kD form. Whereas CD9
binding of the long form appeared to be constitutive, the
short form–CD9 complex increased in the presence of trans-
fected KUZ and with bombesin treatment. Therefore, GPCR
regulates KUZ-dependent activation of HB-EGF by promot-
ing the binding of KUZ to the molecular complex centered
on CD9. Interestingly, the potency of HB-EGF in stimulat-
ing cell growth correlated with its binding to CD9. CD9 also
associates with ADAM2 and regulates interaction of ADAM2
with 
 
 
 
6
 
 
 
1 integrin (Chen et al., 1999; Shi et al., 2000).
Figure 3. Metalloprotease activity of KUZ is responsible for the 
GPCR transactivation EGFR signaling pathway in COS7 cells. 
(A) Transfection of wild-type KUZ, but not K MP, stimulates the 
release of soluble HB-EGF into the medium. The HA-tagged HB-EGF 
in the medium of transfected cells was analyzed by collecting the 
heparin-binding proteins and blotting with the anti-HA antibody 
12CA5. (B) Metalloprotease inhibitor TAPI blocks bombesin-induced 
transactivation of EGFR and SHC. Cells were preincubated with either 
TAPI or solvent DMSO before stimulation with bombesin. The 
immunoprecipitated EGFR or SHC was blotted with antiphospho-
tyrosine antibody 4G10 to reveal the activated EGFR and SHC. 
(C) Catalytically inactive KUZ (K[E-A]) does not support the EGFR 
and SHC transactivation. The total EGFR and SHC was equivalent in 
each lane (not depicted). 
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We have shown that the metalloprotease KUZ defines a
control point in the relay between the GPCR and the EGFR
signaling pathways. The identification of KUZ as the mediator
of transactivation reveals an evolutionarily conserved role of
KUZ in coordinating cell behavior. EGFR transactivation oc-
curs not only in the same cell where both KUZ and EGFR re-
side, but also affects the neighboring cells that sense released
HB-EGF. By relaying the extracellular signal from GPCR to
EGFR, KUZ not only propagates the signal laterally on the cell
membrane, but also coordinates the response of surrounding
cells with cleaved HB-EGF. Interestingly, two other well-
defined KUZ functions also involve the precise control of signals
between adjacent cells: in lateral inhibition where KUZ medi-
ates cleavage of Notch and its ligand Delta (Pan and Rubin,
1997; Qi et al., 1999), and in interaction and cleavage of eph-
rin-A2 upon binding to its receptor Eph in the contacting cell
(Hattori et al., 2000). In all cases, KUZ functions at the point
of cell–cell contact. Elucidation of the mechanism of GPCR
activation of KUZ increases our understanding of how metal-
loprotease-mediated shedding regulates signaling pathways.
 
Materials and methods
 
Cells and constructs
 
COS7 and PC3 cells were cultured in six-well plates with DME to 90% of
confluence before transfection with plasmid DNAs premixed with
Fugene6 (Roche). 12 h after transfection, cells were washed three times
and incubated for an additional 24–36 h in the serum-free medium. Mouse
KUZ (a gift from D.J. Pan, University of Texas Southwestern Medical
School, Dallas, TX), protease-deleted KUZ, ADAM17 (TACE; a gift from R.
Black, Immunex Corporation, Seattle, WA), and ADAM15 were tagged
with the Flag epitope at COOH termini in the same expression vector.
 
EGFR activation assay
 
Transfected cells were treated with GPCR agonists (LPA, 10 
 
 
 
M; bombe-
sin, 200 nM) for 5 min at 37
 
 
 
C before being washed with cold PBS and
lysed in the lysis buffer (50 mM Hepes, pH 7.5, 150 mM NaCl, 1% Triton
 
X-100, 1 mM EDTA, 10% glycerol, 10 mM sodium pyrophosphate, 2 mM
sodium orthovanadate, 10 mM sodium fluoride, plus protease inhibitors).
Cell lysates were cleared by spinning at 15,000 rpm for 10 min and di-
luted with an equal volume of dilution buffer (50 mM Hepes, pH 7.5, 150
mM NaCl, 0.1% Triton X-100, 1 mM EDTA, 10% glycerol, 10 mM so-
dium pyrophosphate, 2 mM sodium orthovanadate, 10 mM sodium fluo-
ride). EGFRs were precipitated from lysates with a polyclonal antibody
(Upstate Biotechnology) overnight at 4
 
 
 
C. The precipitates were blotted
with an antiphosphotyrosine antibody (4G10) to detect the activated
EGFR, and a polyclonal antibody against EGFR (Santa Cruz Biotechnol-
ogy, Inc.) to detect the quantities of EGFR. In some experiments, cells
treated with CRM197 (10 
 
 
 
g/ml), AG1487 (250 nM), or DMSO for 20 min
were then stimulated with agonist for 5 min. Metalloprotease inhibitor
TAPI was applied at 50 
 
 
 
M in DMSO for 40 min at 37
 
 
 
C before stimula-
tion with bombesin.
 
Assay for SHC, Gab1, Ras, and Erk1/2 activation
 
COS7 cells transfected with KUZ, K
 
 
 
MP, and vector for 24 h were serum
starved for an additional 24 h before stimulation with bombesin for 5 min
at 37
 
 
 
C. Adaptor protein SHC or Gab1 was immunoprecipitated with anti-
SHC or anti-Gab1 polyclonal antibody (Transduction Lab). Activation of
SHC or Gab1 was detected in immunoblots as the phosphorylation of SHC
or Gab1 with antiphosphotyrosine antibody 4G10. The activated Ras was
precipitated from the same set of cell lysates with the Ras-binding domain
of Raf1 supplied in a reagent kit (Upstate Biotechnology). The amount of
activated Ras in the cells was detected in the immunoblot with anti-Ras
antibody. Phosphorylation of Erk1/2 was detected with the anti–phospho-
ERK1/2 antibody (New England Biolabs, Inc.) in cell lysates.
 
Antisense experiment
 
Morpholino antisense oligonucleotide to human ADAM10 (AATTAA-
CACTCTCAGCAACACCATC) and control morpholino oligonucleotide
that has the same base composition but in reverse sequence (CTACCA-
CAACGACTCTCACAATTAA) were synthesized by GeneTools, LLC.
Oligos were introduced into PC3 cells with ethoxylated polyethylen-
imine as the delivery reagent according to the procedure recommended
by the manufacturer. PC3 cells in a six-well plate were incubated with
1.5 ml of 1 
 
 
 
M oligo mixture per well for 3 h at 37
 
 
 
C. Cells were
washed and incubated in serum-free medium for an additional 36 h be-
fore stimulation with bombesin and assaying for Erk1/2 phosphoryla-
tion. The endogenous ADAM10 levels in antisense oligo–treated cells
were detected with a polyclonal antibody to ADAM10 (KUZ; Chemicon
International, Inc.).
 
Shedding of HB-EGF
 
COS7 cells were transfected with vector, KUZ–Flag, K
 
 
 
MP–Flag, and he-
magglutinin (HA)-tagged HB-EGF (a gift from M. Klagsburn, Children’s
Hospital, Boston, MA). After bombesin treatment for 20 min, serum-free
media was collected and cleared by spinning at 15,000 rpm for 10 min.
Heparin-binding proteins were precipitated from the medium with hep-
arin-agarose at 4
 
 
 
C overnight and immunoblotted with an anti-HA anti-
body (12CA5) to detect HB-EGF.
 
Immunoprecipitation of CD9
 
COS7 cells were transfected with KUZ–Flag and HA-tagged HB-EGF with
Fugene 6. After stimulating cells with bombesin for 5 min, cell lysates were
prepared in a buffer containing 50 mM Hepes, pH 7.5, 150 mM NaCl, 10
mM CHAPS, 1 mM EDTA, 10% glycerol, 10 mM sodium pyrophosphate, 2
mM sodium orthovanadate, 10 mM sodium fluoride, plus protease inhibi-
tors. CD9 in cell lysates was precipitated with a polyclonal anti-CD9 anti-
body (4 
 
 
 
g/ml, Santa Cruz Biotechnology, Inc.) overnight, and blotted with
monoclonal antibodies against CD9 (BD Biosciences) or HA epitope
(12CA5; Roche).
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Figure 4. GPCRs regulate the formation of a complex of CD9 with 
KUZ and HB-EGF. COS7 cells were transfected with Flag-tagged KUZ 
and HA-tagged HB-EGF. CD9 was precipitated from CHAPS lysates 
of control or bombesin-treated cells with a polyclonal anti-CD9 
antibody. Proteins from the immunoprecipitation were blotted with 
monoclonal antibodies against Flag epitope, HA epitope, and CD9, 
respectively. 
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